| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_396aeb28bc88a1d7d71ab8e38b212420 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-555
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-62
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-645
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-6093
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55533
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55527
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-80 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0011
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6933
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4748
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-385 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| filingDate |
2019-12-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d81c0bc440a4a612f91b0e1085a6ca22 |
| publicationDate |
2020-07-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-3122676-A1 |
| titleOfInvention |
Phagocytisable particle for use in the treatment or prophylaxis of cancer |
| abstract |
The invention provides a phagocytosable particle for use in the treatment or prophylaxis of cancer in a subject, wherein the phagocytosable particle comprises a core and a neoantigenic construct tightly associated to the core, and wherein the neoantigenic construct comprises a neoepitope peptide having an amino acid sequence corresponding to an amino acid sequence of a part of a protein or peptide known or suspected to be expressed by a cancer cell in the subject, wherein the part of the protein or peptide has at least one somatic mutated amino acid. The invention also relates to injectable pharmaceutical compositions for use in the treatment or prophylaxis of cancer. |
| priorityDate |
2018-12-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |